Market Analysis - Oncology And Radiology 2020
In France, three million people have survived cancer. The disease has doubled in 45 years. In 2015, 385,000 new cases of cancer were recorded in France. IN 2015 - 211,000 new cases among men and 174,000 among women (average age of 68 to 67 years). In France, between 2007 and 2016, the number of new cases of cancer was estimated at 356 556 per year and the number of deaths between 2007 and 2014 was 152 556 per year. In 2008, about 12.7 million cases and 7.6 million cancer deaths are estimated 56% of cases and 64% of deaths in the world in economic development. Prostate cancer, the most common tumor in men, has an increasingly favorable prognosis, with an overall survival rate of 76%, higher in young adults. Ovarian cancer has a very varied prognosis according to age: whereas 70% of subjects aged 15 to 44 years survive this form of cancer, this is the case only for 19% of over 74 years.
The global cancer / tumor profiling market valued at $13.30 billion in 2012. By the end of 2013, the market was estimated at $14.99 billion and is expected to reach about $35 billion in 2018, with compound annual growth rate of 18.50%. 2018. Global spending on oncology reached $91 billion in 2013 and grew by 5% annually, reaching $100 billion in 2015. Key players in the cancer and tumor market are Boreal Genomics Inc. (United States), Caris Life Sciences. (United States), Genomic Health Inc. (United States), Illumina Inc. (United States), Life Technologies Corporation (United States), NeoGenomics Laboratories (United States), Oxford Gene Technology Ltd. (United Kingdom), Precision Therapeutics Inc. (United States), bioTheranostics (United States), Proteome Sciences PLC (United Kingdom), Agendia (Netherlands), Nanostring Technologies (United States), Rational Therapeutics (United States), United States), Oncopath Laboratories (United States) and RiboMedBiotechnologies Inc. (WE.). The global cancer diagnostic market is expected to reach $13.1 billion in 2020, up from about $7.1 billion in 2015, with a CAGR of 12.9%.
The market is dominated by North America, followed by Europe, Asia and the rest of the world. The Asian cancer diagnostic market is expected to grow at its fastest pace from 2015 to 2020. According to the market, the global market for oncology drugs is expected to reach $111.9 billion by 2020. The patent expires in Key anti-cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin are expected to drive growth in the cancer biosimilar market by 2020.